Codexis, Inc. Announces Pricing of Initial Public Offering

    


    
</pre>
<p>REDWOOD CITY, Calif., <span class="xn-chron">April 22</span> /CNW/ -- Codexis, Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock, at <span class="xn-money">$13.00</span> per share. All shares are being sold by the company. Codexis has granted the underwriters an option to purchase up to an additional 900,000 shares at the initial public offering price to cover overallotments, if any. The common stock will trade on the NASDAQ Global Market under the symbol "CDXS."</p>
<p/>
<p>Credit Suisse Securities (USA) LLC is acting as the book-running manager, with <span class="xn-person">Piper Jaffray</span> & Co., RBC Capital Markets Corporation and Pacific Crest Securities LLC acting as co-managers for the offering.</p>
<p/>
<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.</p>
<p/>
<p>This offering is being made only by means of a prospectus. A final prospectus for the offering may be obtained from the prospectus department of Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, via telephone at 1-800-221-1037.</p>
<pre>
    

    About Codexis
    
</pre>
<p>Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale. Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals.</p>
<pre>
    

    Contact: Lyn Christenson, [email protected], 650-421-8144




    

For further information: Lyn Christenson of Codexis, Inc., [phone], [email protected] Web Site: http://www.codexis.com